PacBio Files 8-K: Operations, Costs, and Financials

Ticker: PACB · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1299130

Sentiment: neutral

Topics: financial-results, operations, disposal-costs

Related Tickers: PACB

TL;DR

PacBio dropped an 8-K on April 16th covering financials and operational updates.

AI Summary

On April 16, 2024, Pacific Biosciences of California, Inc. filed an 8-K report detailing financial results and other events. The filing includes information on the company's operations, costs associated with exits or disposals, and financial statements. Specific financial figures and operational details are expected to be elaborated upon within the full report.

Why It Matters

This 8-K filing provides crucial updates on Pacific Biosciences' financial condition and operational activities, which can impact investor decisions and market perception.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant financial and operational information that may lead to stock price volatility.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', suggesting detailed financial results are included, though specific figures are not in the provided header.

What kind of 'Costs Associated with Exit or Disposal Activities' are mentioned?

The filing lists 'Cost Associated with Exit or Disposal Activities' as an item, but the nature and amount of these costs are not specified in the provided header.

Are there any significant 'Other Events' reported?

The filing notes 'Other Events' as a category, but no specific events are detailed in the provided header information.

When was Pacific Biosciences of California, Inc. incorporated?

The company's state of incorporation is listed as Delaware.

What is the primary business of Pacific Biosciences of California, Inc. according to the SIC code?

The Standard Industrial Classification (SIC) code provided is 3826, which corresponds to 'Laboratory Analytical Instruments'.

Filing Stats: 1,157 words · 5 min read · ~4 pages · Grade level 12.3 · Accepted 2024-04-16 08:08:31

Key Financial Figures

Filing Documents

02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On April 16, 2024, Pacific Biosciences of California, Inc. (the "Company") issued a press release providing a business update and announcing certain unaudited preliminary financial results as of and for the quarter ended March 31, 2024 (the "Press Release"). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K, including the sections of the Press Release incorporated by reference herein, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

05. COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES

ITEM 2.05. COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES. On April 16, 2024, the Company announced a plan to reduce its annualized run-rate operating expenses on a non-GAAP basis by $50 million to $75 million by the end of 2024 in relation to the Company's prior guidance of 5% operating expense growth. This plan is designed to better align the Company's organizational structure and resources with its strategic initiatives. At this time, the Company is unable to make a determination of the estimated amount or range of amounts for charges to be incurred in connection with these actions. The Company will provide further details by amendment to this Current Report on Form 8-K at such time as it is able to estimate the costs the Company expects to incur. This Item 2.05 contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements include, but are not limited to, statements related to the Company's expected operating expense reductions, the expected timing of such reduction and the charges and financial impact associated with such reductions. These forward-looking statements are based on the Company's current expectations and inherently involve significant risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of those risks and uncertainties, which include, without limitation, risks related to the Company's operating expense reductions and the Company's ability to accurately estimate the charges associated with such reductions. Other factors that could cause actual results to differ from these forward-looking statements are discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. In addition, the charges asso

01. OTHER EVENTS

ITEM 8.01. OTHER EVENTS. The information set forth in the Press Release, solely to the extent such information references the Company's expectations for preliminary revenue estimates for the quarter ended March 31, 2024 and preliminary cash, cash equivalents and investments balance as of March 31, 2024, together with the paragraph set forth under the heading "Forward-looking statements", is incorporated by reference into Item 8.01 of this Current Report on Form 8-K. The portions of the Press Release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the Press Release are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Because the Company's financial statements as of and for the quarter ended March 31, 2024 have not yet been finalized or audited and remain subject to change, the Company's final results for such periods may differ materially from the unaudited preliminary financial information included in the Press Release. Accordingly, you should not place undue reliance on the unaudited preliminary financial information included in the Press Release.

01. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. 99.1 Press Release issued by Pacific Biosciences of California, Inc. dated April 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Brett Atkins Brett Atkins General Counsel Date: April 16, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing